Reports Q2 revenue $114.8M, consensus $107.03M. "We have delivered another strong quarter of performance in Q2 showcasing the growing customer demand for our precision radiotherapy solutions and the excellent operational execution by the Accuray team amidst challenging macroeconomic conditions," said Suzanne Winter, Chief Executive Officer. "Our teams remain focused on advancing our innovation driven growth agenda so that we can deliver on our promise to improve the outcome and quality of life of patients diagnosed with cancer or neurological disease."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARAY:
